University of Florida
Great Toe Strength (GTS) is a potential clinical biomarker that has been associated with functional mobility and health; Additionally, GTS has been identified in the literature as one of the early symptoms of chemotherapy-induced peripheral neuropathy (CIPN). The purpose of this research study is to evaluate GTS in individuals with CIPN and healthy adults using ToeScale and see how it relates to nerve issues from chemotherapy. Additionally, we aim to assess the usability of the novel GTS assessment device, ToeScale among the participants. As a part of this study visit, you will complete some questionnaires followed by GTS and balance and gait assessments.
Chemotherapy-induced peripheral neuropathy, or CIPN, is a common side effect of cancer treatment. It affects about 30-40% of people with cancer and up to 100% of those who receive chemotherapy that can harm nerves. One of the early signs of CIPN is weakness in the muscles of the great toe, which is associated with movement and balance. Current methods used to measure the strength of the great toe muscles have several drawbacks. They are not very sensitive to changes in strength, require expensive equipment or trained professionals, and can be subjective. To address these limitations, a new po…
Eligibility Criteria for Chemotherapy-Induced Peripheral Neuropathy (CIPN) group: Inclusion Criteria: * At least 18 years of old with the ability to independently raise and low (extend or flex) the great toe * Able to consent and complete questionnaires in English independently and have normal to corrected vision (self-reported) * Within 3 - 6 months of starting chemotherapy and a confirmed diagnosis of CIPN using the current clinical reference standard of Nerve conduction study. Exclusion Criteria: * Comorbidities including but not limited to diabetes, arthritis, hypertension, thyroid dis…
No intervention; observational study
Arctuva estimate
Verify or correct the compensation shown for this listing.